Key Takeaways:
FDA granted accelerated approval to Replimune's vusolimogene oderparepvec-wtpg (TUDRIQEV) plus nivolumab for advanced melanoma on Aug. 6, clearing the therapy after two prior rejections.
"The FDA's approval of TUDRIQEV is a defining milestone for Replimune and, more importantly, for the patients facing advanced melanoma, where the need for safe and effective treatment options remains significant," Sushil Patel, PhD, CEO of Replimune, said.
The approval covers adults with unresectable advanced cutaneous melanoma who progressed on an anti-PD-1-based regimen. In the IGNYTE trial, 91 efficacy-evaluable patients achieved a 24.2 percent objective response rate with a 14.1-month median duration of response. The company reported a Q1 FY2027 net loss of $69.8 million, narrowing from $86.7 million a year earlier, with research and development expenses down to $49.3 million from $57.8 million.
Replimune expects product in the market within 60 days, backed by $195.3 million in cash at June 30 plus $141.0 million in net proceeds from an August equity offering. Continued approval depends on the IGNYTE-3 confirmatory trial, a global phase 3 study comparing TUDRIQEV plus nivolumab against physician's choice, with an overall survival readout expected in 2030.
The approval follows two complete response letters — in July 2025 and April 2026 — both citing concerns that the single-arm IGNYTE design lacked substantial evidence of effectiveness. FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 on July 30 that the efficacy results were evaluable and clinically meaningful, sending Replimune shares up more than 120 percent. The company's stock had fallen nearly 32 percent days earlier as FDA staff raised concerns before the advisory meeting.
The patient population included 80 percent with stage IV disease, 54 percent with PD-L1-negative tumors, and 13 percent with prior adjuvant anti-PD-1 exposure. Treatment was generally well tolerated, with serious adverse reactions in 35 percent of patients and 2.9 percent discontinuing permanently due to adverse events. TUDRIQEV is a genetically modified herpes simplex virus type 1 that preferentially replicates within tumors, triggering immune-mediated tumor cell death and activating a systemic anti-tumor response.
Replimune appointed Michelle DiNapoli as chief commercial officer, effective Aug. 18, bringing more than 25 years of oncology commercialization experience from Deciphera Pharmaceuticals and Genentech. The company also launched ReplimuneConnect Plus, a patient support program covering access, reimbursement, and financial assistance. DiNapoli previously built the U.S. sales force at Deciphera as it grew from a single product to a multi-product organization.
The approval marks Replimune's transition from clinical-stage to commercial-stage operations. Investors will watch IGNYTE-3 enrollment and early launch metrics as the company competes against established melanoma therapies from Bristol Myers Squibb and Merck.
This article is for informational purposes only and does not constitute investment advice.
